{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:53:26Z","timestamp":1775019206555,"version":"3.50.1"},"reference-count":10,"publisher":"Japan Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1507\/endocrj.ej19-0266","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T22:03:56Z","timestamp":1573596236000},"page":"201-210","source":"Crossref","is-referenced-by-count":10,"title":["Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance"],"prefix":"10.1507","volume":"67","author":[{"given":"Hiromi","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Pfizer R&D Japan G.K., Tokyo 151-8589, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shimatsu","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"},{"name":"Current Affiliation: Kusatsu General Hospital, Kusatsu 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Okayama","sequence":"additional","affiliation":[{"name":"Pfizer R&D Japan G.K., Tokyo 151-8589, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc., Tokyo 151-8589, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 (2019) Diagnosis and treatment of hypothalamic pituitary dysfunction.  Nihon Naibunpi Gakkai Zasshi 95 Suppl: 1\u201360. https:\/\/www.jstage.jst.go.jp\/article\/endocrine\/95\/S.May\/95_1\/_article\/-char\/ja\/ (In Japanese).","DOI":"10.1507\/endocrine.95.S.May_1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Shimatsu A, Nagashima M, Hashigaki S, Ohki N, Chihara K (2016) Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly. Endocr J 63: 337\u2013347.","DOI":"10.1507\/endocrj.EJ15-0619"},{"key":"3","unstructured":"3 Nonprofit Organization JAPANESE COMMITTEE FOR CLINICAL LABORATORY PRACTICE (2014) Shared Reference Intervals Available from URL: http:\/\/jccls.org\/techreport\/public_comment_201406.pdf. (in Japanese)"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, et al. (2012) Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 59: 771\u2013780.","DOI":"10.1507\/endocrj.EJ12-0110"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, et al. (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1,288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97: 1589\u20131597.","DOI":"10.1210\/jc.2011-2508"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, et al. (2018) Long-term treatment with pegvisomant: observations from 2,090 acromegaly patients in ACROSTUDY. Eur J Endocrinol 179: 419\u2013427.","DOI":"10.1530\/EJE-18-0616"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tritos NA, Chanson P, Jimenez C, King D, J\u00f6nsson PJ, et al. (2017) Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. Eur J Endocrinol 176: 213\u2013220.","DOI":"10.1530\/EJE-16-0697"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Strasburger CJ, Mattsson A, Wilton P, Aydin F, Hey-Hadavi J, et al. (2018) Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant. Eur J Endocrinol 178: 321\u2013329.","DOI":"10.1530\/EJE-17-0996"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9 Takahashi Y (2014) Endocrine disease: progress in the diagnosis and treatment of acromegaly. Nihon Naika Gakkai Zasshi 103: 825\u2013831 (In Japanese).","DOI":"10.2169\/naika.103.825"},{"key":"10","unstructured":"10 Product Evaluation Report (lanreotide acetate) [June 6, 2012 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau] http:\/\/www.pmda.go.jp\/drugs\/2012\/P201200095\/47030000_22400AMX00734_A100_1.pdf (In Japanese)."}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/2\/67_EJ19-0266\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T03:47:03Z","timestamp":1582948023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/2\/67_EJ19-0266\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej19-0266","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}